NO942228L - Ipsapirone drug preparation - Google Patents
Ipsapirone drug preparationInfo
- Publication number
- NO942228L NO942228L NO942228A NO942228A NO942228L NO 942228 L NO942228 L NO 942228L NO 942228 A NO942228 A NO 942228A NO 942228 A NO942228 A NO 942228A NO 942228 L NO942228 L NO 942228L
- Authority
- NO
- Norway
- Prior art keywords
- hours
- release
- ipsapirone
- drug preparation
- ipsaplron
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Det blir beskrevet Ipsaplron-legemlddeltllberednlnger med midlere frlglvlngshastlghet mellom 80*/5 timer til 8056/13 timer og en inltiell frlgivingshastighet på mindre enn 35* ipsaplron i de første 2 timene av fri- gi vnlngen. Disse tilberedningene har god biotilgjengelighet og lagerstabilltet, og består av dlsfusjonskontrollerte pellets eller erosjonstabletter med definert virke- stoff -frigi ving.Ipsaplron drug delivery preparations are described with average release rates between 80 * / 5 hours to 8056/13 hours and an initial release rate of less than 35 * ipsaplron in the first 2 hours of release. These preparations have good bioavailability and the storage stack, and consist of dlsfusion controlled pellets or erosion tablets with defined active substance release.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4319760A DE4319760A1 (en) | 1993-06-15 | 1993-06-15 | Ipsapiron drug preparation |
Publications (2)
Publication Number | Publication Date |
---|---|
NO942228D0 NO942228D0 (en) | 1994-06-14 |
NO942228L true NO942228L (en) | 1994-12-16 |
Family
ID=6490360
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO942228A NO942228L (en) | 1993-06-15 | 1994-06-14 | Ipsapirone drug preparation |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP0629402A1 (en) |
JP (1) | JPH06345649A (en) |
KR (1) | KR950000150A (en) |
CN (1) | CN1099263A (en) |
AU (1) | AU6345794A (en) |
CA (1) | CA2125620A1 (en) |
CZ (1) | CZ146494A3 (en) |
DE (1) | DE4319760A1 (en) |
FI (1) | FI942803A (en) |
HU (1) | HUT70759A (en) |
IL (1) | IL109993A0 (en) |
NO (1) | NO942228L (en) |
NZ (1) | NZ260732A (en) |
PL (1) | PL303822A1 (en) |
SK (1) | SK72494A3 (en) |
ZA (1) | ZA944187B (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9706089D0 (en) * | 1997-03-24 | 1997-05-14 | Scherer Ltd R P | Pharmaceutical composition |
BR9916835A (en) * | 1998-12-24 | 2001-09-25 | Janssen Pharmaceutica Nv | Controlled-release galantamine composition |
WO2004103338A1 (en) * | 2003-05-19 | 2004-12-02 | Bioprogress Plc | Adhesives and film modifying compositions |
CN114727995B (en) * | 2020-09-02 | 2024-06-11 | 北京华昊中天生物医药股份有限公司 | Solid oral preparation of eutelone |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE79029T1 (en) * | 1989-02-11 | 1992-08-15 | Bayer Ag | CONTROLLED-RELEASE PHARMACEUTICALS. |
DD297767A5 (en) * | 1990-03-06 | 1992-01-23 | Bayer Aktiengesellschaft,De | MEDICINAL PRODUCTS WITH CONTROLLED ACTIVE INGREDIENTS |
JPH04360826A (en) * | 1991-06-07 | 1992-12-14 | Bayer Yakuhin Kk | Controlled release pharmaceutical preparation |
-
1993
- 1993-06-15 DE DE4319760A patent/DE4319760A1/en not_active Withdrawn
-
1994
- 1994-05-31 AU AU63457/94A patent/AU6345794A/en not_active Abandoned
- 1994-06-03 EP EP94108571A patent/EP0629402A1/en not_active Withdrawn
- 1994-06-09 JP JP6150640A patent/JPH06345649A/en active Pending
- 1994-06-10 CA CA002125620A patent/CA2125620A1/en not_active Abandoned
- 1994-06-13 PL PL94303822A patent/PL303822A1/en unknown
- 1994-06-13 IL IL10999394A patent/IL109993A0/en unknown
- 1994-06-13 NZ NZ260732A patent/NZ260732A/en unknown
- 1994-06-13 FI FI942803A patent/FI942803A/en unknown
- 1994-06-14 HU HU9401771A patent/HUT70759A/en unknown
- 1994-06-14 KR KR1019940013308A patent/KR950000150A/en not_active Application Discontinuation
- 1994-06-14 NO NO942228A patent/NO942228L/en unknown
- 1994-06-14 ZA ZA944187A patent/ZA944187B/en unknown
- 1994-06-14 SK SK724-94A patent/SK72494A3/en unknown
- 1994-06-14 CZ CZ941464A patent/CZ146494A3/en unknown
- 1994-06-15 CN CN94106657A patent/CN1099263A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
HUT70759A (en) | 1995-10-30 |
CA2125620A1 (en) | 1994-12-16 |
KR950000150A (en) | 1995-01-03 |
HU9401771D0 (en) | 1994-09-28 |
SK72494A3 (en) | 1995-04-12 |
EP0629402A1 (en) | 1994-12-21 |
CN1099263A (en) | 1995-03-01 |
JPH06345649A (en) | 1994-12-20 |
DE4319760A1 (en) | 1994-12-22 |
AU6345794A (en) | 1994-12-22 |
FI942803A (en) | 1994-12-16 |
IL109993A0 (en) | 1994-10-07 |
CZ146494A3 (en) | 1995-01-18 |
ZA944187B (en) | 1995-02-08 |
FI942803A0 (en) | 1994-06-13 |
PL303822A1 (en) | 1995-01-09 |
NZ260732A (en) | 1996-02-27 |
NO942228D0 (en) | 1994-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2327973A1 (en) | Storage system for powdered pharmaceuticals, and inhaler equipped with this system | |
AU6995794A (en) | Aspb28 insulin crystals | |
TR199802034T2 (en) | �apraz ba�lant�l� amylose ve hydroxypropylmethylcellulose baz�nda bir ta��y�c� i�eren kontroll� ��z�l�ml� farmas�tik tablet. | |
GEP20012442B (en) | Irreversible Inhibitors of Tyrosine Kinases | |
IT8719064A0 (en) | TABLET FOR PHARMACEUTICAL USE SUITABLE FOR THE RELEASE OF ACTIVE SUBSTANCES AT SUBSEQUENT TIMES. | |
DK1171573T3 (en) | ARPE-19, as a platform cell line for encapsulated cell-based administration | |
NO953278D0 (en) | Methods for in vivo delivery of biologically active substances and compositions useful for this purpose | |
AU692430B2 (en) | Aqueous pharmaceutical preparations of G-CSF with a long shelf life | |
UA66417C2 (en) | Recombinant adenovirus affecting canines, pharmaceutical composition | |
AU7315496A (en) | Delivery of biologically active polypeptides | |
CA2029524A1 (en) | Transdermal administration of 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazole | |
WO1994013808A3 (en) | LYMPHOTOXIN-β, LYMPHOTOXIN-β COMPLEXES, PHARMACEUTICAL PREPARATIONS AND THERAPEUTIC USES THEREOF | |
HUP0103669A2 (en) | Multiple unit controlled food effect-independent release pharmaceutical preparations and method for preparing the same | |
CO5011082A1 (en) | DRUG FORMULATION WITH CONTROLLED RELEASE OF ACTIVE SUBSTANCE | |
IT1314185B1 (en) | PHARMACEUTICAL COMPOSITION FOR ADMINISTRATION OF SUBSTANCES ACTIVELY SOLUBLE IN AQUEOUS MEDIA | |
EP0514464A4 (en) | Biologically active amphiphilic peptides and method of inhibiting growth of target cells, virus or virally-infected cell | |
NO942228L (en) | Ipsapirone drug preparation | |
AU687623B2 (en) | Cell Adhesion peptides for use in modifying mutual adhesion among eukaryotic cells | |
CA2185883A1 (en) | The use of dimeticone as a transport and carrier system and/or drug delivery system | |
PT1144420E (en) | PHOSPHATIDILINOSITOIS SULPHATATED TO ITS PREPARATION AND ITS UTILIZATION | |
WO2000063348A3 (en) | Pharmaceutical composition comprising pim-activated nkt cells, and therapeutic use thereof | |
IT9048066A0 (en) | 2- 6, 7-SUSTITUTED AMINOTETRALINES ACTIVE AS IMMUNOMODULANTS AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM. | |
DE59510583D1 (en) | PHARMACEUTICAL COMPOSITION FOR SYSTEMIC TRANSDERMAL ADMINISTRATION WITH THE ACTIVE MORPHINE-6-GLUCURONIDE | |
WO1996015234A3 (en) | Lipid-splitting enzyme | |
EP0906756A4 (en) | Anti-hiv composition containing imidazole derivative |